5.00
+0.8(+19.05%)
Currency In USD
| Previous Close | 4.2 |
| Open | 4.26 |
| Day High | 5.04 |
| Day Low | 4.24 |
| 52-Week High | 5.31 |
| 52-Week Low | 1.84 |
| Volume | 5M |
| Average Volume | 1.28M |
| Market Cap | 255.52M |
| PE | -3.38 |
| EPS | -1.48 |
| Moving Average 50 Days | 2.99 |
| Moving Average 200 Days | 2.92 |
| Change | 0.8 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $1.03 as of October 21, 2025 at a share price of $5. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $571.43 as of October 21, 2025 at a share price of $5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
GlobeNewswire Inc.
12 hours ago
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasd
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
GlobeNewswire Inc.
Oct 17, 2025 11:30 AM GMT
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
GlobeNewswire Inc.
Oct 02, 2025 8:01 PM GMT
SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatm